1
|
Fiorentini G, Zironda A, Fogliati A, Warner S, Cleary S, Smoot R, Truty M, Kendrick M, Nagorney D, Thiels C, Starlinger P. The "double-fired" gastro-jejunostomy as a form of improved efficiency during Whipple procedure. HPB (Oxford) 2024; 26:512-520. [PMID: 38184460 DOI: 10.1016/j.hpb.2023.12.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/10/2023] [Revised: 08/28/2023] [Accepted: 12/08/2023] [Indexed: 01/08/2024]
Abstract
BACKGROUND Gastro-jejunostomy (GJ) after pylorus-resecting pancreatoduodenectomy (PD) is most commonly performed in a hand-sewn fashion. Intestinal stapled anastomosis are reported to be as effective as hand-sewn in terms of patency and risk of leakage in other indications. However, the use of a stapled gastro-jejunostomy hasn't been fully assessed in PD. The aim of the present technical report is to evaluate functional outcomes of stapled GJ during PD, its associated effect on operative time and related complications. METHODS The institutional database for pancreatic duct adenocarcinoma (PDAC) was retrospectically reviewed. Pylorus resecting open PD without vascular or multivisceral resections were considered for the analysis. The incidence of clinically significant delayed gastric emptying (DGE from the International Stufy Group of Pancreatic Surgery (ISGPS) grade B and C), other complications, operative time and overall hospitalization were evaluated. RESULTS Over a 10-years study period, 1182 PD for adenocarcinoma were performed and recorded in the database. 243 open Whipple procedures with no vascular and with no associated multivisceral resections were available and constituted the study population. Hand-sewn (HS) anastomosis was performed in 175 (72 %), stapled anastomosis (St) in 68 (28 %). No significant differences in baseline characteristics were observed between the two groups, with the exception of a higher rate of neoadjuvant chemotherapy in the HS group (74 % St vs. 86 % HS, p = 0.025). Intraoperatively, a significantly reduced median operative time in the St group was observed (248 min St vs. 370 mins HS, p < 0.001). Post-operatively, rates of clinically relevant delayed gastric emptying (7 % St vs. 14 % HS, p = 0.140), clinically relevant pancreatic fistula (10 % St, 15 % HS, p = 0.300), median length of stay (7 days for each group, p = 0.289), post-pancreatectomy hemorrhage (4.4 % St vs. 6.3 % HS, p = 0.415) and complication rate (22 % St vs. 34 % HS, p = 0.064) were similar between groups. However, readmission rates were significantly lower after St GJ (13.2 % St vs 29.7 % HS, p = 0.008). CONCLUSION Our results indicate that a stapled GJ anastomosis during a standard Whipple procedure is non-inferior to a hand-sewn GJ, with a comparable rate of DGE and no increase of gastrointestinal related long term complications. Further, a stapled GJ anastomosis might be associated with reduced operative times.
Collapse
Affiliation(s)
- G Fiorentini
- Hepatobiliary and Pancreas Division, Mayo Clinic, Rochester, MN, USA
| | - A Zironda
- Hepatobiliary and Pancreas Division, Mayo Clinic, Rochester, MN, USA
| | - A Fogliati
- Hepatobiliary and Pancreas Division, Mayo Clinic, Rochester, MN, USA
| | - S Warner
- Hepatobiliary and Pancreas Division, Mayo Clinic, Rochester, MN, USA
| | - S Cleary
- Hepatobiliary and Pancreas Division, Mayo Clinic, Rochester, MN, USA
| | - R Smoot
- Hepatobiliary and Pancreas Division, Mayo Clinic, Rochester, MN, USA
| | - M Truty
- Hepatobiliary and Pancreas Division, Mayo Clinic, Rochester, MN, USA
| | - M Kendrick
- Hepatobiliary and Pancreas Division, Mayo Clinic, Rochester, MN, USA
| | - D Nagorney
- Hepatobiliary and Pancreas Division, Mayo Clinic, Rochester, MN, USA
| | - C Thiels
- Hepatobiliary and Pancreas Division, Mayo Clinic, Rochester, MN, USA
| | - P Starlinger
- Hepatobiliary and Pancreas Division, Mayo Clinic, Rochester, MN, USA.
| |
Collapse
|
2
|
Meusel V, Mentzakis E, Baji P, Fiorentini G, Paolucci F. Priority setting in the German healthcare system: results from a discrete choice experiment. Int J Health Econ Manag 2023; 23:411-431. [PMID: 37184821 PMCID: PMC10462569 DOI: 10.1007/s10754-023-09347-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/29/2020] [Accepted: 03/04/2023] [Indexed: 05/16/2023]
Abstract
Worldwide, social healthcare systems must face the challenges of a growing scarcity of resources and of its inevitable distributional effects. Explicit criteria are needed to define the boundaries of public reimbursement decisions. As Germany stands at the beginning of such a discussion, more formalised priority setting procedures seem in order. Recent research identified multi-criteria decision analysis (MCDA) as a promising approach to inform and to guide decision-making in healthcare systems. In that regard, this paper aims to analyse the relative weight assigned to various criteria in setting priority interventions in Germany. A discrete choice experiment (DCE) was employed in 2015 to elicit equity and efficiency preferences of 263 decision makers, through six attributes. The experiment allowed us to rate different policy interventions based on their features in a composite league table (CLT). As number of potential beneficiaries, severity of disease, individual health benefits and cost-effectiveness are the most relevant criteria for German decision makers within the sample population, the results display an overall higher preference towards efficiency criteria. Specific high priority interventions are mental disorders and cardiovascular diseases.
Collapse
Affiliation(s)
- V Meusel
- Faculty of Medicine, FAU Erlangen-Nürnberg, Erlangen, Germany.
| | - E Mentzakis
- Department of Economics, City University of London, Northampton Square, London, EC1V 0HB, UK
| | - P Baji
- Department of Health Economics, Corvinus University of Budapest, Budapest, Hungary
| | - G Fiorentini
- Department of Economics, University of Bologna, Bologna, Italy
| | - F Paolucci
- Sir Walter Murdoch School of Public Policy and International Affairs, Murdoch University, Perth, WA, Australia
- Department of Sociology and Law & Economics, University of Bologna, Bologna, Italy
| |
Collapse
|
3
|
Fiorentini G, Ratti F, Cipriani F, Aldrighetti L. ASO Author Reflections: The SMART-ALPPS Protocol-Strategy to Minimize ALPPS Risks by Targeting Invasiveness. Ann Surg Oncol 2021; 28:6828-6829. [PMID: 33791904 DOI: 10.1245/s10434-021-09957-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2021] [Accepted: 03/24/2021] [Indexed: 01/18/2023]
Affiliation(s)
- G Fiorentini
- Hepatobiliary Surgery Division, IRCCS San Raffaele Hospital, Milan, Italy. .,PhD School in Experimental Medicine, University of Pavia, Pavia, Italy.
| | - F Ratti
- Hepatobiliary Surgery Division, IRCCS San Raffaele Hospital, Milan, Italy
| | - F Cipriani
- Hepatobiliary Surgery Division, IRCCS San Raffaele Hospital, Milan, Italy
| | - L Aldrighetti
- Hepatobiliary Surgery Division, IRCCS San Raffaele Hospital, Milan, Italy.,University Vita-Salute San Raffaele, Milan, Italy
| |
Collapse
|
4
|
Fiorentini G, Ratti F, Cipriani F, Quattromani R, Catena M, Paganelli M, Aldrighetti L. The SMART-ALPPS Protocol: Strategy to Minimize ALPPS Risks by Targeting Invasiveness. Ann Surg Oncol 2021; 28:6826-6827. [PMID: 33625636 DOI: 10.1245/s10434-021-09711-7] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/27/2021] [Indexed: 01/24/2023]
Abstract
BACKGROUND The range of procedures with documented feasibility by laparoscopic approach is widening in the setting of liver resections. Many technical limits have been overcome in the attempt to reduce the biological impact of major procedures [1-8]. Similarly, associated liver partition and portal vein ligation for staged hepatectomy (ALPPS)-which could be assumed as the paradigm of maxi-invasiveness-has recently been proposed in a minimally invasive fashion to reduce the impact of this procedure [9-12]. Technical insights to perform laparoscopic ALPPS are provided. METHODS Perioperative and intraoperative tips for laparoscopic ALPPS are provided within a SMART (Strategy to Minimize ALPPS Risks by Targeting invasiveness) protocol. Stage 1: After volumetric and functional assessment, partial liver transection is performed, keeping intact both the hilum and the caval plane (to prevent adhesions), therefore avoiding portal ligation. No inert material is left inside the abdominal cavity at the end of procedure to keep the liver surfaces apart. Radiologic portography with portal vein embolization is scheduled on postoperative day (POD) 1. Liver volume (pre-PVE: 29%; post-PVE: 52%) and liver function measured through a Technetium-99 hepatobiliary scintigraphy [13] (pre-PVE: 2.15%/min/sqm; post-PVE: 3.67%/min/sqm) of the future remnant liver are reassessed within 10 days to verify whether size and function are adequate. Stage 2: After 2 weeks from the first stage, laparoscopic right hepatectomy is performed following an anterior approach. RESULTS No conversion to open was required. Operative time was 100 and 300 minutes for stage 1 and 2, respectively. Intraoperative blood loss was 50 and 300 ml for the two procedures. Postoperative course was uneventful; patient was discharged on POD 6 of the second operation. CONCLUSIONS The implementation of a perioperative protocol to prevent the risk of liver failure by both assessing volume and function of FLR and targeting the invasiveness of the surgical procedure may allow to minimize and control risks of a maximally invasive procedure, such as ALPPS.
Collapse
Affiliation(s)
- G Fiorentini
- Hepatobiliary Surgery Division, IRCCS San Raffaele Hospital, Milan, Italy. .,PhD School in Experimental Medicine, University of Pavia, Pavia, Italy.
| | - F Ratti
- Hepatobiliary Surgery Division, IRCCS San Raffaele Hospital, Milan, Italy
| | - F Cipriani
- Hepatobiliary Surgery Division, IRCCS San Raffaele Hospital, Milan, Italy
| | - R Quattromani
- Hepatobiliary Surgery Division, IRCCS San Raffaele Hospital, Milan, Italy
| | - M Catena
- Hepatobiliary Surgery Division, IRCCS San Raffaele Hospital, Milan, Italy
| | - M Paganelli
- Hepatobiliary Surgery Division, IRCCS San Raffaele Hospital, Milan, Italy
| | - L Aldrighetti
- Hepatobiliary Surgery Division, IRCCS San Raffaele Hospital, Milan, Italy.,University Vita-Salute San Raffaele, Milan, Italy
| |
Collapse
|
5
|
Guerra F, Sarti D, Eugeni E, Patriti A, Fiorentini G. Immunomodulation after HIPEC of peritoneal carcinomatosis by monitoring the immune response in 6 patients. Eur J Surg Oncol 2020. [DOI: 10.1016/j.ejso.2020.06.068] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
6
|
Cazzaniga ME, Pinotti G, Montagna E, Amoroso D, Berardi R, Butera A, Cagossi K, Cavanna L, Ciccarese M, Cinieri S, Cretella E, De Conciliis E, Febbraro A, Ferraù F, Ferzi A, Fiorentini G, Fontana A, Gambaro AR, Garrone O, Gebbia V, Generali D, Gianni L, Giovanardi F, Grassadonia A, Leonardi V, Marchetti P, Melegari E, Musolino A, Nicolini M, Putzu C, Riccardi F, Santini D, Saracchini S, Sarobba MG, Schintu MG, Scognamiglio G, Spadaro P, Taverniti C, Toniolo D, Tralongo P, Turletti A, Valenza R, Valerio MR, Vici P, Clivio L, Torri V. Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study. Breast 2019; 48:7-16. [PMID: 31470257 DOI: 10.1016/j.breast.2019.07.006] [Citation(s) in RCA: 30] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2019] [Revised: 07/24/2019] [Accepted: 07/29/2019] [Indexed: 12/21/2022] Open
Abstract
Metronomic chemotherapy (mCHT) refers to the minimum biologically effective dose of a chemotherapy agent given as a continuous dosing regimen, with no prolonged drug-free breaks, that leads to antitumor activity. Aim of the present study is to describe the use of mCHT in a retrospective cohort of metastatic breast cancer (MBC) patients in order to collect data regarding the different types and regimens of drugs employed, their efficacy and safety. Between January 2011 and December 2016, data of 584 metastatic breast cancer patients treated with mCHT were collected. The use of VRL-based regimens increased during the time of observation (2011: 16.8% - 2016: 29.8%), as well as CTX-based ones (2011: 17.1% - 2016: 25.6%), whereas CAPE-based and MTX-based regimens remained stable. In the 1st-line setting, the highest ORR and DCR were observed for VRL-based regimens (single agent: 44% and 88%; combination: 36.7% and 82.4%, respectively). Assuming VRL-single agent as the referee treatment (median PFS: 7.2 months, 95% CI: 5.3-10.3), the longest median PFS were observed in VRL-combination regimens (9.5, 95%CI 88.8-11.3, HR = 0.72) and in CAPE-single agent (10.7, 95%CI 8.3-15.8, HR = 0.70). The VICTOR-6 study provides new data coming from the real-life setting, by adding new information regarding the use of mCHT as an option of treatment for MBC patients.
Collapse
Affiliation(s)
- M E Cazzaniga
- Research Unit Phase I Trials, ASST Monza, Monza, Italy; Oncology Unit, ASST Monza, Italy.
| | - G Pinotti
- Medical Oncology, ASST Sette Laghi "Ospedale di Circolo e Fondazione Macchi, Varese, VA, Italy
| | - E Montagna
- Medical Senology Division, IEO, Milan, Italy
| | - D Amoroso
- Medical Oncology, Ospedale Della Versilia, Lido di Camaiore, IT, Italy
| | - R Berardi
- Medical Oncology, A. Ospedaliero-universitaria Ospedali Riuniti, Ancona, IT, Italy
| | - A Butera
- Medical Oncology, Ospedale San Giovanni di Dio, Agrigento, IT, Italy
| | - K Cagossi
- Medical Oncology, Ospedale Ramazzini, Carpi, IT, Italy
| | - L Cavanna
- Medical Oncology, Azienda Ospedaliera Piacenza, Piacenza, IT, Italy
| | - M Ciccarese
- Medical Oncology, Ospedale Vito Fazzi, Lecce, IT, Italy
| | - S Cinieri
- Medical Oncology, ASL Brindisi, Brindisi, Italy
| | - E Cretella
- Medical Oncology, Ospedale Bolzano, IT, Italy
| | | | - A Febbraro
- Medical Oncology, Ospedale S. Cuore di Gesù Fatebenefratelli, Benevento, Italy
| | - F Ferraù
- Medical Oncology, Osp Taormina, Taormina, IT, Italy
| | - A Ferzi
- Medical Oncology, A.S.S.T. Ovest Milanese, Legnano, IT, Italy
| | - G Fiorentini
- Medical Oncology, Ospedale San Salvatore, Pesaro, Italy
| | - A Fontana
- Medical Oncology, Az. Ospedaliero-Universitaria, Pisana, IT, Italy
| | - A R Gambaro
- Medical Oncology, ASST Fatebenefratelli, Sacco, IT, Italy
| | - O Garrone
- Medical Oncology, A.O. S. Croce e Carle, Cuneo, Italy
| | - V Gebbia
- Medical Oncology, Ospedale La Maddalena, Palermo, IT, Italy
| | - D Generali
- Medical Oncology, Istituti Ospitalieri Cremona, Cremona, IT, Italy
| | - L Gianni
- Medical Oncology, Azienda USL Romagna, U.O. di Oncologia Rimini, Cattolica, IT, Italy
| | - F Giovanardi
- Medical Oncology, Ospedale Civile, Guastalla, IT, Italy
| | - A Grassadonia
- Medical Oncology, P.O. SS Annunziata -ASL2 Lanciano-Vasto, Chieti, IT, Italy
| | - V Leonardi
- Medical Oncology, Ospedale Civico, Palermo, IT, Italy
| | - P Marchetti
- Medical Oncology, A.O. Sant'Andrea, Roma, IT, Italy
| | - E Melegari
- Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - A Musolino
- Medical Oncology, Azienda Ospedaliero-Universitaria di Parma, IT, Italy
| | - M Nicolini
- Medical Oncology, Azienda USL Romagna, U.O. di Oncologia Rimini, Cattolica, IT, Italy
| | - C Putzu
- Medical Oncology, A. Ospedaliera-Universitaria, Sassari, IT, Italy
| | - F Riccardi
- Medical Oncology, A. Ospedaliera Antonio Cardarelli, Napoli, IT, Italy
| | - D Santini
- Medical Oncology Università Campus Bio-Medico, Roma, IT, Italy
| | - S Saracchini
- Medical Oncology, Az. Osp. Santa Maria Degli Angeli, Pordenone, IT, Italy
| | - M G Sarobba
- Medical Oncology, Ospedale San Francesco, Nuoro, IT, Italy
| | - M G Schintu
- Medical Oncology, Osp Giovanni Paolo II, Olbia, IT, Italy
| | | | - P Spadaro
- Medical Oncology, Casa di Cura Villa Salus, Messina, IT, Italy
| | - C Taverniti
- Medical Oncology, A.O.U. Città Della Salute e Della Scienza, Osp. Molinette, Torino, IT, Italy
| | - D Toniolo
- Medical Oncology, ASST Rhodense 3 Ospedale di Circolo Rho, IT, Italy
| | - P Tralongo
- Medical Oncology, Osp. Umberto I, Siracusa, IT, Italy
| | - A Turletti
- Medical Oncology, P.O. Martini, Torino, IT, Italy
| | - R Valenza
- Medical Oncology, P.O. Vittorio Emanuele, Gela, IT, Italy
| | - M R Valerio
- Medical Oncology, A.O.U. Policlinico Paolo Giaccone, Palermo, IT, Italy
| | - P Vici
- Medical Oncology, B, INT Regina Elena, Roma, IT, Italy
| | - L Clivio
- Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Italy
| | - V Torri
- Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Italy
| | | |
Collapse
|
7
|
Khoja L, Atenafu E, Suciu S, Leyvraz S, Sato T, Marshall E, Keilholz U, Zimmer L, Patel S, Piperno-Neumann S, Piulats J, Kivelä T, Pfoehler C, Bhatia S, Huppert P, Van Iersel L, De Vries I, Penel N, Vogl T, Cheng T, Fiorentini G, Mouriaux F, Tarhini A, Patel P, Carvajal R, Joshua A. Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study. Ann Oncol 2019; 30:1370-1380. [DOI: 10.1093/annonc/mdz176] [Citation(s) in RCA: 99] [Impact Index Per Article: 19.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
|
8
|
Fiorentini G, Ratti F, Cipriani F, Cinelli L, Catena M, Paganelli M, Aldrighetti L. Theory of Relativity for Posterosuperior Segments of the Liver. Ann Surg Oncol 2019; 26:1149-1157. [PMID: 30675701 DOI: 10.1245/s10434-019-07165-6] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2018] [Indexed: 12/12/2022]
Abstract
BACKGROUND The accessibility to posterosuperior segments of the liver has traditionally constituted a restrain to adopt the laparoscopic approach in this setting. To overcome this challenge, multiple approaches have been reported in literature. Total transabdominal approach has been previously described for this purpose, even though the rationale to standardly adopt it and a technical depiction of how to achieve an optimal mobilization has never been specifically addressed. METHODS Total transabdominal purely laparoscopic approach to posterosuperior segments of the liver is presented, with detailed emphasis to the rotational motions targeted in laparoscopy. A literature review is presented to summarize all other possible accesses to posterosuperior area of the liver. The institutional series for the laparoscopic approach to Sg 7, Sg 6+7, and Sg8 is retrospectively described. RESULTS Three rotational motions of the liver are specifically addressed in a video presentation and described for the laparoscopic total-transabdominal approach; the local institutional series using this approach is presented. Other miscellaneous approaches identified from literature encompassing variations in operative position, transabdominal, transthoracic, and combined approaches are described. CONCLUSIONS Complete mobilization of the ligaments of the liver leads to a rotation of the transection line in front of the operator's view, allowing to achieve a safe total trans-abdominal laparoscopic approach to the posterosuperior ligaments of the liver, without compromising the vascular inflow control, the possibility to convert to open approach, nor requiring potentially harmful decubitus.
Collapse
Affiliation(s)
- G Fiorentini
- Hepatobiliary Surgery Division, IRCCS San Raffaele Hospital, Milan, Italy.
| | - F Ratti
- Hepatobiliary Surgery Division, IRCCS San Raffaele Hospital, Milan, Italy
| | - F Cipriani
- Hepatobiliary Surgery Division, IRCCS San Raffaele Hospital, Milan, Italy
| | - L Cinelli
- Hepatobiliary Surgery Division, IRCCS San Raffaele Hospital, Milan, Italy
| | - M Catena
- Hepatobiliary Surgery Division, IRCCS San Raffaele Hospital, Milan, Italy
| | - M Paganelli
- Hepatobiliary Surgery Division, IRCCS San Raffaele Hospital, Milan, Italy
| | - L Aldrighetti
- Hepatobiliary Surgery Division, IRCCS San Raffaele Hospital, Milan, Italy
| |
Collapse
|
9
|
Torrecilhas J, Dallantonia E, Lima L, Simioni T, Alves K, Lage J, Fiorentini G, Berchielli T. PSIX-25 Meat quality of young cattle fed with different nutritional plans on growing phase and finished in pasture or feedlot. J Anim Sci 2018. [DOI: 10.1093/jas/sky404.618] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- J Torrecilhas
- São Paulo State University (Unesp), School of Agricultural and Veterinarian Sciences,Jaboticabal, Jaboticabal, Brazil
| | - E Dallantonia
- São Paulo State University (Unesp), School of Agricultural and Veterinarian Sciences,Jaboticabal, Jaboticabal, Brazil
| | - L Lima
- São Paulo State University (Unesp), School of Agricultural and Veterinarian Sciences,Jaboticabal, Jaboticabal, Brazil
| | - T Simioni
- São Paulo State University (Unesp), School of Agricultural and Veterinarian Sciences,Jaboticabal, Jaboticabal, Brazil
| | - K Alves
- São Paulo State University (Unesp), School of Agricultural and Veterinarian Sciences,Jaboticabal, Jaboticabal, Brazil
| | - J Lage
- Trouw Nutrition,Campinas, Brazil
| | - G Fiorentini
- São Paulo State University (Unesp), School of Agricultural and Veterinarian Sciences,Jaboticabal, Jaboticabal, Brazil
| | - T Berchielli
- São Paulo State University (Unesp), School of Agricultural and Veterinarian Sciences,Jaboticabal, Jaboticabal, Brazil
| |
Collapse
|
10
|
Fiorentini G, Messana J, José Neto A, Sgobi E, Castagnino P, Berchielli T. Performance and meat quality of Nellore bulls fed crude glycerin combined with soybean oil. Anim Feed Sci Technol 2018. [DOI: 10.1016/j.anifeedsci.2018.04.013] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
11
|
Cantore M, Fiorentini G, Aitini E, Davitti B, Cavazzini G, Rabbi C, Lusenti A, Bertani M, Morandi C, Benedini V. Intra-Arterial Hepatic Carboplatin-Based Chemotherapy for Ocular Melanoma Metastatic to the Liver. Report of a Phase II Study. Tumori 2018; 80:37-9. [PMID: 8191596 DOI: 10.1177/030089169408000107] [Citation(s) in RCA: 36] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Aims and Background ocular melanoma tends to metastasize to the liver, sparing for a long time the rest of the organism. Therefore, a regional treatment is especially indicated. Methods eight patients with ocular melanoma metastatic to the liver were treated with intraarterial hepatic carboplatin-based chemotherapy at the dose of 300 mg/m2 once every two weeks at an outpatient clinic. All the patients were submitted to laparotomy with surgical implantation of an arterial port device through the gastroduodenal artery. Results the overall response rate was 38% with a median survival time of 15 months. The regimen was well tolerated and the principle toxicity was myelosuppression; any instance of hepatic and/ or cholangitic damage was reported. Conclusions Carboplatin seems suitable for intraarterial hepatic chemotherapy and active in ocular melanoma metastic to the liver.
Collapse
Affiliation(s)
- M Cantore
- Oncology Department, Civil Hospital of Mantova, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Abstract
Aims and Background Hepatocellular carcinoma (HCC) ranks third of cancer deaths in China, it kills 100,000 patients every year. In Italy HCC is an increasing malignant tumor and kills about 7000 patients every year. Fortunately, due to a multimodal approach to the treatment of this fatal disease, HCC has been changed from « Incurable » to « partly curable ». The authors report and comment the methods and the strategies that have been used to increase the cure-rate of HCC. Methods The actual approaches, developed in the last thirty years mainly in China, included: screening of cirrhotic patients, early resection, new surgical criteria for cirrhotic liver, early detection of subclinical recurrence and re-resection, multimodality treatment for cytoreduction of huge HCC, sequential resection after cytoreduction of unresectable HCC, targeting therapy using radiolabelled antibodies and lipiodol, transarterial embolization, radiotherapy combined with Chinese herbs, other regional cancer therapy and biological response modifiers. Results Are that these methods have reached a marked increase series 5-year survival rate and number of 5-year survivors in more expert institutions. Conclusions We conclude that further biological and genetic studies on HCC are warranted and that it is mandatory to perform large clinical randomized trials comparing the more promising treatments.
Collapse
Affiliation(s)
- Z Y Tang
- Liver Cancer Institute, Shanghai Medical University, People's Republic of China
| | | |
Collapse
|
13
|
Cruciani G, Tienghi A, Molinari AL, Fiorentini G, Rosti G, Turci D, Marangolo M. Cyclophosphamide, Methotrexate, 5-Fluorouracil, Alternating with Adriamycin and Mitomycin C in Metastatic Breast Cancer: A Pilot Study. Tumori 2018; 73:303-7. [PMID: 3111046 DOI: 10.1177/030089168707300316] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
To explore the clinical applicability of the Goldie and Coldman hypothesis, we treated 28 patients with metastatic breast cancer with alternating non-cross-resistant chemotherapy. The patients received cyclophosphamide, 600 mg/m2, 5-fluorouracil, 600 mg/m2, methotrexate, 40 mg/m3, alternated every three weeks with adriamycin, 60 mg/m2, and mitomycin C, 10 mg/m2. Only one patient had previously received palliative chemotherapy. Six patients had received adjuvant CMF, and 17 patients had been pretreated with endocrine therapy (13 for advanced disease, 4 as adjuvant). Fourteen patients had bone involvement, and 10 had visceral metastases. A mean of 12 cycles was given to 24 evaluable patients. The objective response rate was 67%: 11 patients (46%) achieved complete and 5 (21%) partial remission. Response rate in soft tissues was 83.3%, in bone 50%, in liver 100%, and in lung 80%. The median duration of response was 14 months, with 7 patients still in remission. No life-threatening toxicity was observed. Our preliminary results support the validity of this approach and the efficacy of this combination chemotherapy. A large-scale randomized study is warranted.
Collapse
|
14
|
Fiorentini G, Lucchi SR, Giovanis P, Cantore M, Guadagni S, Papiani G. Irinotecan Hepatic Arterial Infusion Chemotherapy for Hepatic Metastases from Colorectal Cancer: Results of a Phase I Clinical Study. Tumori 2018; 87:388-90. [PMID: 11989591 DOI: 10.1177/030089160108700606] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Background Hepatic arterial infusion chemotherapy is a promising approach in liver metastases from colorectal cancer, but chemical hepatitis, biliary sclerosis, arterial thrombosis and right upper quadrant pain are limiting factors. Irinotecan (CPT-11) is an active drug in colorectal cancer. We planned a short hepatic arterial infusion of CPT-11 to describe the toxicity, to determine the dose-limiting toxicity, and to define the doses of CPT-11 to be recommended for phase II studies. Patients and Methods Fourteen patients with a median liver substitution of 30% (10-60%) were enrolled. All patients received hepatic arterial infusion chemotherapy with CPT-11 on an outpatient basis every 3 weeks as a short, 30-min infusion. Results At 240 mg/m2, 2 of 4 patients experienced grade 4 diarrhea and neutropenia, and 3 of them also reported grade 4 abdominal pain of the right upper quadrant. The maximum tolerated dose was reached at 240 mg/m2. The recommended doses of CPT-11 for phase II studies is 200 mg/m2, given every 3 weeks. Conclusions CPT-11 presents a low hepatic toxic profile and could be considered a new active drug, suitable for hepatic arterial infusion in liver metastases from colorectal cancer.
Collapse
Affiliation(s)
- G Fiorentini
- Department of Oncology and Hematology, City Hospital S Maria delle Croci, Ravenna, Italy.
| | | | | | | | | | | |
Collapse
|
15
|
Fiorentini G, Ratti F, Cipriani F, Catena M, Paganelli M, Aldrighetti L. Tips and Tricks for a Laparoscopic Approach to Paracaval Liver Segments. Ann Surg Oncol 2018; 25:1695-1698. [PMID: 29600345 DOI: 10.1245/s10434-018-6432-7] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2017] [Indexed: 12/12/2022]
Abstract
BACKGROUND A dramatic spread of laparoscopic liver surgery has been experienced over the last years. The approach to paracaval liver segments 1 and 9 is still poorly described in literature, mainly due to its technical demands. OBJECTIVE The aim of this article was to introduce a safe and effective approach to paracaval liver segments through laparoscopy. METHODS A minimally invasive approach to resection of Segments 1 and 9 is presented, and an operative set-up is depicted. A step-by-step technique describing the inferior vena cava (IVC) with left and right hepatic venous junction exposure, segmental pedicle isolation, and parenchymal transection is shown through a video document. RESULTS Postoperative courses were uneventful, and patients were discharged on postoperative day 3. DISCUSSION The approach to paracaval liver segments requires accurate preoperative case selection, technical, surgical, and anesthesiological expertise in laparoscopic liver surgery, and adequate instrumentary. CONCLUSION Paracaval segments of the liver can be approached safely through laparoscopy by teams with extensive expertise in the field of laparoscopic liver surgery; however, suspected malignant infiltration of the IVC or unclear preoperative anatomy still contraindicate this approach.
Collapse
Affiliation(s)
- G Fiorentini
- Hepatobiliary Surgery Division, IRCCS San Raffaele Hospital, Milan, Italy.
| | - F Ratti
- Hepatobiliary Surgery Division, IRCCS San Raffaele Hospital, Milan, Italy
| | - F Cipriani
- Hepatobiliary Surgery Division, IRCCS San Raffaele Hospital, Milan, Italy
| | - M Catena
- Hepatobiliary Surgery Division, IRCCS San Raffaele Hospital, Milan, Italy
| | - M Paganelli
- Hepatobiliary Surgery Division, IRCCS San Raffaele Hospital, Milan, Italy
| | - L Aldrighetti
- Hepatobiliary Surgery Division, IRCCS San Raffaele Hospital, Milan, Italy
| |
Collapse
|
16
|
Ribeiro AF, Messana JD, Neto AJ, Lage JF, Fiorentini G, Vieira BR, Berchielli TT. Enteric methane emissions, intake, and performance of young Nellore bulls fed different sources of forage in concentrate-rich diets containing crude glycerine. Anim Prod Sci 2018. [DOI: 10.1071/an15645] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Forty young Nellore bulls were used to determine the effects of different sources of forage in concentrate-rich diets containing crude glycerine on feed intake, performance, and enteric methane emissions. Ten animals (397 ± 34 kg and 20 ± 2 months of age) were slaughtered to estimate the initial carcass weights, and the remaining 30 animals (417 ± 24.7) were randomly assigned to three treatments with 10 replicates. The treatments consisted of three different sources of forage [NDF from forage (fNDF) was fixed 15% of dry matter]; corn silage, sugarcane, and sugarcane bagasse; in diets rich in concentrates with 10% dry matter crude glycerine. There were no differences in the intake of dry matter, organic matter, crude protein, neutral detergent fibre, gross energy, or metabolisable energy. No effects of the type of forage were observed on performance or enteric methane emissions. These results suggest that alternatives to corn silage that have high fibre content, such as sugarcane and sugarcane bagasse, do not significantly affect the intake, performance, or enteric methane emissions of young Nellore bulls.
Collapse
|
17
|
Fiorentini G, Sarti D, Carandina R, Nardella M, Mulazzani L, Barnes Navarro D, Mugnos Gomez F, Zoras O, Aliberti C. Arterially directed embolic therapy (ADET) with polyethylene glycol microspheres loaded with irinotecan for refractory liver metastases from colorectal cancer. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx422.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
18
|
Fiorentini G, Sarti D, Carandina R, Nardella M, Mulazzani L, Felicioli A, Barnes Navarro D, Mugnos Gomez F, Zoras O, Aliberti C. Polyethylene glycol embolics loaded with irinotecan for chemoembolization of refractory liver metastases from colorectal cancer. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx393.037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
19
|
Santana MCA, Fiorentini G, Messana JD, Dian PHM, Canesin RC, Reis RA, Berchielli TT. Different forms and frequencies of soybean oil supplementation do not alter rumen fermentation in grazing heifers. Anim Prod Sci 2017. [DOI: 10.1071/an14608] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Over the productive cycle, the performance of cattle in grazing systems may be compromised, and feed supplementation is a strategy to establish nutritional balance and maximise the performance of grazing animals. The objective of this study was to evaluate the effect of different supplementation frequencies (i.e. daily supplementation (DS) versus Monday, Wednesday and Friday (MWF)) with different forms of soybean oil (i.e. soybean grain (SG), soybean oil (SO) and rumen-protected fat (RPF)) on the nutrient digestion and rumen fermentation of heifers grazing Brachiaria brizantha cv. Marandu pastures. Twelve crossbred heifers (1/4 Nellore × 1/4 Santa Gertrudis × 1/2 Braunvieh) with an initial bodyweight of 236.3 ± 27.6 kg were distributed in a completely randomised design with a factorial arrangement 3 × 2 (three diets and two supplementation frequencies). There was no interaction among the SO form or supplementation frequency on dry matter intake and dry matter digestibility (P > 0.05). The animals supplemented with SG exhibited lower nitrogen intake and absorption compared with animals that were fed SO (P < 0.05). The efficiency of microbial synthesis was not influenced by the diet or supplementation frequency (P > 0.05). Forms of SO affected the rumen pH; animals fed SO showed pH values similar to those of animals receiving SG but lower values than animals fed RPF (P < 0.05). Animals supplemented with DS exhibited higher levels of rumen ammonia nitrogen relative to those supplemented MWF. The reduction of supplementation frequency (from DS to MWF k) in our experimental conditions can be used to increase the efficiency of pasture utilisation without effects in fermentation activity of the rumen microbial population. Supplementation with SO is a strategy to increase propionic acid concentration and reduce A : P ratio, which is an indicator of improvement of the efficiency of the ruminal energy utilisation.
Collapse
|
20
|
Rossi LG, Fiorentini G, Jose Neto A, Vieira BR, Malheiros EB, Borghi TH, Berchielli TT. Impact of ground soybean and starch levels on the quality of meat from feedlot young Nellore bulls. Meat Sci 2016; 122:1-6. [PMID: 27458839 DOI: 10.1016/j.meatsci.2016.07.013] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2016] [Revised: 07/20/2016] [Accepted: 07/20/2016] [Indexed: 11/26/2022]
Abstract
Twenty-eight young Nellore bulls (395±32kg initial body weight) were assigned to a completely randomized design (2×2 factorial design with 7 animals per treatment) to evaluate effects on the quality of meat. Diet treatments consisted of high (about 25%) or low (about 16%) starch levels, with or without ground soybean addition. Shear force was decreased in the meat from animals fed a low-starch diet (P=0.0016). Meat from animals fed a high-starch diet had increased total concentrations of unsaturated (P=0.0029) and monounsaturated fatty acids (P=0.0253). Polyunsaturated fatty acid content increased in the meat from animals fed a diet containing soybean (P=0.0121). High starch diets (>25%) decreased the concentration of saturated fatty acids and increased the amount of unsaturated fatty acids in the meat from young Nellore bulls.
Collapse
Affiliation(s)
- L G Rossi
- Animal Science Department, Universidade Estadual Paulista Julio de Mesquita Filho (Unesp), Campus Jaboticabal, CEP 14884-900 Jaboticabal, SP, Brazil
| | - G Fiorentini
- Animal Science Department, Universidade Estadual Paulista Julio de Mesquita Filho (Unesp), Campus Jaboticabal, CEP 14884-900 Jaboticabal, SP, Brazil.
| | - A Jose Neto
- Animal Science Department, Universidade Estadual Paulista Julio de Mesquita Filho (Unesp), Campus Jaboticabal, CEP 14884-900 Jaboticabal, SP, Brazil
| | - B R Vieira
- Animal Science Department, Universidade Estadual Paulista Julio de Mesquita Filho (Unesp), Campus Jaboticabal, CEP 14884-900 Jaboticabal, SP, Brazil
| | - E B Malheiros
- Animal Science Department, Universidade Estadual Paulista Julio de Mesquita Filho (Unesp), Campus Jaboticabal, CEP 14884-900 Jaboticabal, SP, Brazil
| | - T H Borghi
- Animal Science Department, Universidade Estadual Paulista Julio de Mesquita Filho (Unesp), Campus Jaboticabal, CEP 14884-900 Jaboticabal, SP, Brazil
| | - T T Berchielli
- Animal Science Department, Universidade Estadual Paulista Julio de Mesquita Filho (Unesp), Campus Jaboticabal, CEP 14884-900 Jaboticabal, SP, Brazil; INCT/CA - UFV - Department of Animal Science, Av. Peter Henry Rolfs s/n, Campus Universitário, CEP 36570-000 Viçosa, MG, Brazil
| |
Collapse
|
21
|
Bernardeschi P, Dentico P, Rossi S, Fiorentini G, Giustarini G, Montenora I, Turano E. Chemoresistant Myeloma: Phase II Clinical Study with Low-Dose Thalidomide Plus High-Dose Dexamethasone. J Chemother 2016; 16 Suppl 5:90-3. [PMID: 15675489 DOI: 10.1080/1120009x.2004.11782395] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
Thalidomide produces a response rate from 32 to 66% of pre-treated myeloma patients with doses ranging from 100 to 800 mg/daily. Common, dose-related side effects are sedation, constipation, polyneuropathy. Increased incidence of thromboembolic events were observed in myeloma patients receiving thalidomide as front-line therapy or in association with chemotherapy. Less common adverse reactions are central nervous system (CNS) dysfunction and cutaneous reactions. We describe the update of our experience with low dose thalidomide plus monthly high dose dexamethasone and zolendronate. Most patients were able to tolerate this regimen with few side effects. Erythrocyte sedimentation rate (ESR) lowering was early observed in patients who subsequently responded.
Collapse
|
22
|
Guadagni S, Müller H, Valenti M, Clementi M, Fiorentini G, Cantore M, Amicucci G. Thoracic Stop-Flow Perfusion in the Treatment of Refractory Non Small Cell Lung Cancer. J Chemother 2016; 16 Suppl 5:40-3. [PMID: 15675476 DOI: 10.1080/1120009x.2004.11782382] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
This study was undertaken to determine the survival of patients with unresectable and refractory non small cell lung cancer (NSCLC) submitted to thoracic stop-flow perfusion (TSP). Forty-five patients with NSCLC confined to thoracic region entered the study. All 45 patients had been pretreated with some form of chemotherapy and had progression of disease. The cytostatic regimen was mitomycin 10 mg/m2, navelbine 25 mg/m2 and cisplatin 60 mg/m2. In 39/45 patients, immediately after TSP, hemofiltration was performed to reduce systemic side effects There were 16/45 responses to the first TSP (CR 0; PR 16): a response rate of 35.6%. Median time to progression was 4 months. Median survival was 7.5 months.1-year survival rate was 36.4%, 2-year survival rate was 14%, and 3-year survival rate was 5.7%.
Collapse
Affiliation(s)
- S Guadagni
- Dept of Surgical Sciences, University of L'Aquila, L'Aquila, Italy.
| | | | | | | | | | | | | |
Collapse
|
23
|
Fiorentini G, Carrandina R, Sarti D, Mulazzani L, Felicioli A, Coschiera P, Catalano V, Aliberti C. Hepatic arterial infusion of Polythylene Glycol drug-eluting beads for Primary liver cancer therapy. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw333.24] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
24
|
Aliberti C, Carandina R, Sarti D, Giordani P, Catalano V, Mulazzani L, Fiorentini G. Transarterial Chemoembolization using Polythylene Glycol drug-eluting beads pre-charged with irinotecan (LIFIRI®) for the treatment of Metastatic liver cancer: preliminary results. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw335.33] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
25
|
Graziano F, Ruzzo A, Giacomini E, Ricciardi T, Aprile G, Loupakis F, Lorenzini P, Ongaro E, Zoratto F, Catalano V, Sarti D, Rulli E, Cremolini C, De Nictolis M, De Maglio G, Falcone A, Fiorentini G, Magnani M. Glycolysis gene expression analysis and selective metabolic advantage in the clinical progression of colorectal cancer. Pharmacogenomics J 2016; 17:258-264. [DOI: 10.1038/tpj.2016.13] [Citation(s) in RCA: 62] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/26/2015] [Revised: 01/26/2016] [Accepted: 01/27/2016] [Indexed: 01/16/2023]
|
26
|
Casadei V, Cecchini S, Sarti D, Ricci S, Serresi S, Ricotti G, Mulazzani L, Alessandroni P, Luzi Fedeli S, Fiorentini G. Isolated limb infusion chemotherapy with or without hemofiltration for recurrent limb melanoma. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv337.06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
27
|
Fiorentini G, Aliberti C, Sarti D, Coschiera P, Tilli M, Mulazzani L, Giordani P, Graziano F, Marqués Gonzalez A, García Marcos R, Gómez Mugnoz F, Cantore M, Ricci S, Catalano V, Mambrini A. DEBIRI and cetuximab (DEBIRITUX) as a secondline treatment for unresectable colorectal liver metastases (UCLM): results of a phase II trial exploring a new sequence. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv340.23] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
28
|
Ongaro E, Ruzzo A, Giacomini E, Ricciardi T, Aprile G, Loupakis F, Lorenzini P, Zoratto F, Cremolini C, Catalano V, Sarti D, Rullia E, De Nictolis M, DeMaglio G, Falcone A, Fiorentini G, Magnani M, Graziano F. Glucose metabolism enzymes gene expression analysis and selective metabolic advantage in the clinical progression of colorectal cancer (CRC). Ann Oncol 2015. [DOI: 10.1093/annonc/mdv340.49] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
29
|
Agostini M, Appel S, Bellini G, Benziger J, Bick D, Bonfini G, Bravo D, Caccianiga B, Calaprice F, Caminata A, Cavalcante P, Chepurnov A, Choi K, D’Angelo D, Davini S, Derbin A, Di Noto L, Drachnev I, Empl A, Etenko A, Fiorentini G, Fomenko K, Franco D, Gabriele F, Galbiati C, Ghiano C, Giammarchi M, Goeger-Neff M, Goretti A, Gromov M, Hagner C, Houdy T, Hungerford E, Ianni A, Ianni A, Jedrzejczak K, Kaiser M, Kobychev V, Korablev D, Korga G, Kryn D, Laubenstein M, Lehnert B, Litvinovich E, Lombardi F, Lombardi P, Ludhova L, Lukyanchenko G, Machulin I, Manecki S, Maneschg W, Mantovani F, Marcocci S, Meroni E, Meyer M, Miramonti L, Misiaszek M, Montuschi M, Mosteiro P, Muratova V, Neumair B, Oberauer L, Obolensky M, Ortica F, Otis K, Pagani L, Pallavicini M, Papp L, Perasso L, Pocar A, Ranucci G, Razeto A, Re A, Ricci B, Romani A, Roncin R, Rossi N, Schönert S, Semenov D, Simgen H, Skorokhvatov M, Smirnov O, Sotnikov A, Sukhotin S, Suvorov Y, Tartaglia R, Testera G, Thurn J, Toropova M, Unzhakov E, Vogelaar R, von Feilitzsch F, Wang H, Weinz S, Winter J, Wojcik M, Wurm M, Yokley Z, Zaimidoroga O, Zavatarelli S, Zuber K, Zuzel G. Spectroscopy of geoneutrinos from 2056 days of Borexino data. Int J Clin Exp Med 2015. [DOI: 10.1103/physrevd.92.031101] [Citation(s) in RCA: 69] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
30
|
Pistilli B, Benedetti G, Rossi D, Baldelli A, Magalotti C, Casadei V, Foghini L, Staffolani M, Fiorentini G, Latini L. P211 Phase 2 neoadjuvant trial: myocet (M), cyclophosphamide (C) +/− trastuzumab (T) and paclitaxel (P) +/− T. Breast 2015. [DOI: 10.1016/s0960-9776(15)70245-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
31
|
Castagnino P, Messana J, Fiorentini G, de Jesus R, San Vito E, Carvalho I, Berchielli T. Glycerol combined with oils did not limit biohydrogenation of unsaturated fatty acid but reduced methane production in vitro. Anim Feed Sci Technol 2015. [DOI: 10.1016/j.anifeedsci.2014.12.004] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
32
|
Santana M, Fiorentini G, Dian P, Canesin R, Messana J, Oliveira R, Reis R, Berchielli T. Growth performance and meat quality of heifers receiving different forms of soybean oil in the rumen. Anim Feed Sci Technol 2014. [DOI: 10.1016/j.anifeedsci.2014.05.001] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
33
|
Fiorentini G, Carvalho IPC, Messana JD, Castagnino PS, Berndt A, Canesin RC, Frighetto RTS, Berchielli TT. Effect of lipid sources with different fatty acid profiles on the intake, performance, and methane emissions of feedlot Nellore steers. J Anim Sci 2014; 92:1613-20. [PMID: 24492580 DOI: 10.2527/jas.2013-6868] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
The present study was conducted to evaluate the effect of lipids with different fatty acid profiles on the intake, performance, and enteric CH4 emission of Nellore steers. A total of 45 Nellore animals with an average initial BW of 419 ± 11 kg (at 15 ± 2 mo) were distributed in a completely randomized design consisting of 5 treatments and 9 replicates. The roughage feed was maize silage (600 g/kg on a DM basis) plus concentrate (400 g/kg on a DM basis). The dietary treatments were as follows: without additional fat (WF), palm oil (PO), linseed oil (LO), protected fat (PF; Lactoplus), and whole soybeans (WS). The lipid source significantly affected (P < 0.05) nutrient intake. The greatest intakes of DM, OM, and CP were observed in the animals that were fed the WF or PF diets, and the lowest intakes were observed in the animals that were fed the PO diet. Intake of NDF decreased (P < 0.05) with the addition of PO. Enteric methane emission (g/kg DMI) was reduced by an average of 30% when the animals were fed diets containing WS, LO, and PO (P < 0.05), and these diets caused a larger reduction in the energy loss in the form of methane compared to those without added fat and with added PF (3.3 vs. 4.7%). The different fatty acid profiles did not affect the backfat thickness or the loin eye area of the animals (P > 0.05). However, animals fed PO displayed lower daily weight gain (0.36 kg/d), feed efficiency (0.08 kg ADG/kg DM), HCW (245 kg), and hot yield percentage (52.6%) compared to animals that were fed the other diets. Therefore, PO compared to the other lipid sources used in this study reduces intake, performance, feed efficiency, and carcass yield. Therefore, PO is not suggested for feedlot-finished animals.
Collapse
Affiliation(s)
- G Fiorentini
- Department of Animal Science, São Paulo State University (UNESP)/Campus Jaboticabal, Rod. Professor Paulo Donato Castellane, km 5, Rural, Jaboticabal, São Paulo, Brazil, CEP: 14884-900
| | | | | | | | | | | | | | | |
Collapse
|
34
|
Morais J, Queiroz M, Keli A, Vega A, Fiorentini G, Canesin R, Reis R, Berchielli T. Effect of supplementation frequency on intake, behavior and performance in beef steers grazing Marandu grass. Anim Feed Sci Technol 2014. [DOI: 10.1016/j.anifeedsci.2014.01.005] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
35
|
Pistilli B, Rossi D, Benedetti G, Baldelli AM, Decembrini-Cognigni P, Casadei V, Ciccioli G, Ranaldi R, Fiorentini G, Latini L. Abstract P3-14-16: A phase 2 trial of myocet®, cyclophosphamide +/- trastuzumab followed by weekly paclitaxel +/- trastuzumab as primary systemic therapy in operable and locally advanced breast cancer. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p3-14-16] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND: Anthracycline- and taxane-based chemotherapies are highly effective in primary systemic treatment of breast cancer (BC). Myocet® (M) is a non-pegylated liposomal doxorubicin exhibiting reduced cardiotoxicity as compared to doxorubicin. Combination of M and cyclophosphamide (C) has demonstrated efficacy in first line treatment of metastatic BC, however few data are available in neoadjuvant setting, especially in combination with trastuzumab (T). The aims of the study were activity, in terms of pathological complete response (pCR; ie, no remaining invasive tumor in breast and lymphnodes) and safety of a sequential schedule of M and C +/- T followed by weekly paclitaxel (P) +/- T. METHODS: Estrogen receptor (ER), progesterone receptor (PgR), HER2 positivity (defined as 3+ overexpression by immunoistochemical testing or HER2 amplification by fluorescent in situ hybridisation) and Ki67 index were assessed in core needle biopsies at baseline and in residual tumour after chemotherapy. Patients with stage II/III BC received 4 cycles of MC (myocet 60 mg/m2, cyclophosphamide 600 mg/m2 on day 1 every 3 weeks), followed by 12 weekly doses of P (paclitaxel 80 mg/m2); all patients with HER2+ disease received T in combination with chemotherapy (trastuzumab loading dose of 8 mg/kg followed by 3 cycles of 6 mg/kg alongside MC; 2 mg/kg per week with the following 12 P administrations). RESULTS: 49 patients were enrolled, with 44 patients having completed chemotherapy and undergoing surgery to date. Median age was 56 years (range, 34 to 72). Tumour characteristics were as follows: stage IIA 10 patients, IIB 16, IIIA 13, IIIB 5, IIIC 1, and 4 patients with inflammatory BC; ER+/PgR+ 21 patients, ER+/PgR- 13, triple negative 8, HER2+ 16; Ki67> 15% in 41 patients. Forty-four patients were evaluable for pathological response. pCR was obtained in 12 patients (27.3%). The rate of pCR in HER2+ and HER2- BC was 57.1% and 13.3%, respectively. Clinical response was obtained in 36 out of 41 clinically evaluable patients (87.8%): CR in 20 (48.8%) and PR in 16 (39%). Conservative surgery was performed in 16 patients (36.4%) and mastectomy in 28 (63.6%). The most frequently observed grade 3-4 AEs were: alopecia 47 patients (95.9%), grade 3 neutropenia 2 (4.1%), febrile neutropenia 2 (4,1%), grade 3 paresthesia 2 (4.1%), grade 3 vomiting 1 (2%), grade 3 cutaneous erythema 1 (2%). Only 1 patient experienced an asymptomatic decrease of ejection fraction lower than 50%. Five patients (10.2%) discontinued treatment with M+C because of: allergic reaction to M in 3 patients, grade 2 liver toxicity in 1 and grade 3 vomiting in 1. All of them completed the following treatment with P. Three patients (6.1%) discontinued P because of: allergic reaction in 1 patient, infectious pneumonia in 1 and grade 3 cutaneous erythema in 1. CONCLUSIONS: The use of M in this sequential anthracycline- and taxane-based regimen resulted tolerable even in combination with T and active despite of the high rate of patients with ER+ disease and with locally advanced cancer. Consistently with previous data, pCR was higher in patients with HER2+ BC.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P3-14-16.
Collapse
Affiliation(s)
- B Pistilli
- Oncology Unit-Area Vasta 3, Macerata, MC, Italy; Ospedali Riuniti Marche Nord, Pesaro, PU, Italy; Surgery Unit-Area Vasta 3, Civitanova Marche, MC, Italy; Radiology Unit-Area Vasta 3, Macerata, MC, Italy; Pathology Unit-Area Vasta 3, Macerata, MC, Italy
| | - D Rossi
- Oncology Unit-Area Vasta 3, Macerata, MC, Italy; Ospedali Riuniti Marche Nord, Pesaro, PU, Italy; Surgery Unit-Area Vasta 3, Civitanova Marche, MC, Italy; Radiology Unit-Area Vasta 3, Macerata, MC, Italy; Pathology Unit-Area Vasta 3, Macerata, MC, Italy
| | - G Benedetti
- Oncology Unit-Area Vasta 3, Macerata, MC, Italy; Ospedali Riuniti Marche Nord, Pesaro, PU, Italy; Surgery Unit-Area Vasta 3, Civitanova Marche, MC, Italy; Radiology Unit-Area Vasta 3, Macerata, MC, Italy; Pathology Unit-Area Vasta 3, Macerata, MC, Italy
| | - AM Baldelli
- Oncology Unit-Area Vasta 3, Macerata, MC, Italy; Ospedali Riuniti Marche Nord, Pesaro, PU, Italy; Surgery Unit-Area Vasta 3, Civitanova Marche, MC, Italy; Radiology Unit-Area Vasta 3, Macerata, MC, Italy; Pathology Unit-Area Vasta 3, Macerata, MC, Italy
| | - P Decembrini-Cognigni
- Oncology Unit-Area Vasta 3, Macerata, MC, Italy; Ospedali Riuniti Marche Nord, Pesaro, PU, Italy; Surgery Unit-Area Vasta 3, Civitanova Marche, MC, Italy; Radiology Unit-Area Vasta 3, Macerata, MC, Italy; Pathology Unit-Area Vasta 3, Macerata, MC, Italy
| | - V Casadei
- Oncology Unit-Area Vasta 3, Macerata, MC, Italy; Ospedali Riuniti Marche Nord, Pesaro, PU, Italy; Surgery Unit-Area Vasta 3, Civitanova Marche, MC, Italy; Radiology Unit-Area Vasta 3, Macerata, MC, Italy; Pathology Unit-Area Vasta 3, Macerata, MC, Italy
| | - G Ciccioli
- Oncology Unit-Area Vasta 3, Macerata, MC, Italy; Ospedali Riuniti Marche Nord, Pesaro, PU, Italy; Surgery Unit-Area Vasta 3, Civitanova Marche, MC, Italy; Radiology Unit-Area Vasta 3, Macerata, MC, Italy; Pathology Unit-Area Vasta 3, Macerata, MC, Italy
| | - R Ranaldi
- Oncology Unit-Area Vasta 3, Macerata, MC, Italy; Ospedali Riuniti Marche Nord, Pesaro, PU, Italy; Surgery Unit-Area Vasta 3, Civitanova Marche, MC, Italy; Radiology Unit-Area Vasta 3, Macerata, MC, Italy; Pathology Unit-Area Vasta 3, Macerata, MC, Italy
| | - G Fiorentini
- Oncology Unit-Area Vasta 3, Macerata, MC, Italy; Ospedali Riuniti Marche Nord, Pesaro, PU, Italy; Surgery Unit-Area Vasta 3, Civitanova Marche, MC, Italy; Radiology Unit-Area Vasta 3, Macerata, MC, Italy; Pathology Unit-Area Vasta 3, Macerata, MC, Italy
| | - L Latini
- Oncology Unit-Area Vasta 3, Macerata, MC, Italy; Ospedali Riuniti Marche Nord, Pesaro, PU, Italy; Surgery Unit-Area Vasta 3, Civitanova Marche, MC, Italy; Radiology Unit-Area Vasta 3, Macerata, MC, Italy; Pathology Unit-Area Vasta 3, Macerata, MC, Italy
| |
Collapse
|
36
|
Vrekoussis T, Stathopoulos EN, De Giorgi U, Kafousi M, Pavlaki K, Kalogeraki A, Chrysos E, Fiorentini G, Zoras O. Modulation of Vascular Endothelium by Imatinib: A Study on the EA.hy 926 Endothelial Cell Line. J Chemother 2013; 18:56-65. [PMID: 16572895 DOI: 10.1179/joc.2006.18.1.56] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
In this study the EA.hy 926 endothelial cell line--simulating endothelial cells--was treated with imatinib in order to define a possible anti-angiogenic role for imatinib. Dose and time response experiments were performed. Cell morphology was studied, while migration efficiency, intercellular permeability and VE-cadherin expression were assayed, both in the presence and in the absence of imatinib. Imatinib-induced EA.hy 926 cell apoptosis was also examined. Results showed that imatinib reduced the endothelial cell population, changed cell monolayer morphology and reduced cell-to-cell cohesiveness. Migration efficiency was significantly decreased while intercellular permeability was 2.76-fold increased in the presence of imatinib. Indirect immunofluorescence microscopy showed nearly complete down-regulation of VE cadherin in imatinib-treated cells. Furthermore, apoptotic activity was detected in imatinib-treated cells. Altogether our results support an antiangiogenic profile for imatinib that possibly contributes to its therapeutic potential.
Collapse
Affiliation(s)
- T Vrekoussis
- Department of General Surgery, University Hospital and Medical School, University of Crete, Greece
| | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Fiorentini G, Rossi S, Bonechi F, Vaira M, De Simone M, Dentico P, Bernardeschi P, Cantore M, Guadagni S. Intra-Arterial Hepatic Chemoembolization in Liver Metastases from Neuroendocrine Tumors: A Phase II Study. J Chemother 2013; 16:293-7. [PMID: 15330328 DOI: 10.1179/joc.2004.16.3.293] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
Abstract
Neuroendocrine tumors, particularly those of gastrointestinal tract origin, have a predisposition for metastasizing to the liver, causing parenchymal substitution and paraneoplastic syndrome. Lipiodol embolization combined with anticancer drugs is a recent tool in regional therapy. It has been proven that chemoembolization reduces tumor bulk and hormone levels, and that it palliates the symptoms of many patients with liver-dominant neuroendocrine metastases. Beginning in December 1988, ten patients with unresectable and chemotherapy-refractory liver metastatic neuroendocrine tumors were treated with chemoembolization based on a mixture of lipiodol, mitomycin, cisplatin, epirubicin, followed by gelfoam powder and contrast media. Toxicity encountered included: upper right quadrant pain requiring narcotics, elevation of lactate dehydrogenase, alkaline phosphatase, and transaminases. One patient had liver abscess and persistent fever for 2 weeks. We obtained two complete remissions lasting 12 and 34 months and 5 partial remissions. The median survival was 22 months. Four patients had urinary elevation of 5-hydroxyindolacetic acid (5-HIAA). They showed more than a 75% decrease in urinary secretion after treatment. In a patient with transplanted liver we noticed a partial response lasting 7 months. We conclude that chemoembolization will improve the clinical condition of a significant percentage of patients with liver metastases, that future therapy of carcinoid tumors will be based on specific tumor biology and that treatment will be customized for each individual patient combining the use of cytoreductive procedures including radiofrequency ablation, laser treatment and chemoembolization.
Collapse
Affiliation(s)
- G Fiorentini
- Oncology Department, San Giuseppe General Hospital, Empoli (Firenze), Italy.
| | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Cantore M, Fiorentini G, Luppi G, Rosati G, Caudana R, Piazza E, Comella G, Ceravolo C, Miserocchi L, Mambrini A, Del Freo A, Zamagni D, Rabbi C, Marangolo M. Ceravolo. J Chemother 2013; 16:589-94. [PMID: 15700852 DOI: 10.1179/joc.2004.16.6.589] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
Abstract
Gemcitabine is considered the gold standard treatment for unresectable pancreatic adenocarcinoma. Intra-arterial drug administration had shown some interesting results in small phase II studies. In this study, patients were randomly assigned to receive gemcitabine at a dose of 1,000 mg/m2 over 30 minutes intravenously weekly for 7 weeks, followed by 1 week of rest, then weekly for 3 weeks every 4 weeks or FLEC: 5-fluoruracil 1,000 mg/m2, leucovorin 100 mg/m2, epirubicin 60 mg/m2, carboplatin 300 mg/m2 infused bolus intra-arterially into celiac axis at a 3-week interval 3 times or 5-fluorouracil 400 mg/m2 plus folinic acid 20 mg/m2 for 5 days every 4 weeks for 6 cycles. The primary endpoint was overall survival, while time to treatment failure, response rate, clinical benefit response were secondary endpoints. Sixty-seven patients were randomly allocated gemcitabine and 71 were allocated FLEC intra-arterially. Patients treated with FLEC lived for significantly longer than patients on gemcitabine (p=0.036). Survival at 1 year increased from 21% in the gemcitabine group to 35% in the FLEC group. Median survival was 7.9 months in the FLEC group and 5.8 months in the gemcitabine group. Median time to treatment failure was longer with FLEC (5.3 vs 4.2 months for FLEC vs gemcitabine respectively; p=0.013). Clinical benefit was similar in both groups (17.9% for gemcitabine and 26.7% for FLEC; p=NS). CT-scan partial response was similar in both groups (5.9% for gemcitabine and 14% for FLEC; p=NS). Toxicity profiles were different. Compared with gemcitabine, the FLEC regimen given intra-arterially improved survival in patients with unresectable pancreatic adenocarcinoma.
Collapse
Affiliation(s)
- M Cantore
- Oncological Department, USL 1, Massa and Carrara, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Xhixha G, Ahmeti A, Bezzon GP, Bitri M, Broggini C, Buso GP, Caciolli A, Callegari I, Cfarku F, Colonna T, Fiorentini G, Guastaldi E, Mantovani F, Massa G, Menegazzo R, Mou L, Prifti D, Rossi Alvarez C, Sadiraj Kuqi D, Shyti M, Tushe L, Xhixha Kaçeli M, Zyfi A. First characterisation of natural radioactivity in building materials manufactured in Albania. Radiat Prot Dosimetry 2013; 155:217-223. [PMID: 23315825 DOI: 10.1093/rpd/ncs334] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
This study focuses on the radiological characterisation of building materials manufactured in Albania by using a high-resolution gamma-ray spectrometer. The average activity concentrations of (40)K, (226)Ra and (232)Th were, respectively, 644.1±64.2, 33.4 ± 6.4 and 42.2 ± 7.6 Bq kg(-1) in the clay brick samples and 179.7 ± 48.9, 55.0 ± 5.8 and 17.0 ± 3.3 Bq kg(-1) in the cement samples. The calculated activity concentration index (ACI), varied from 0.48±0.02 to 0.63±0.04 in the clay brick samples and from 0.29±0.03 to 0.37±0.02 in the cement samples. Based on the ACI, all of the clay brick and cement samples were categorised as A1 materials. The authors can exclude (at 3σ level) any restriction of their use as bulk materials.
Collapse
Affiliation(s)
- G Xhixha
- Istituto Nazionale di Fisica Nucleare (INFN), Legnaro National Laboratory, Via dell'Università, 2, Legnaro, Padova 35020, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Fiorentini G, Messana J, Dian P, Reis R, Canesin R, Pires A, Berchielli T. Digestibility, fermentation and rumen microbiota of crossbred heifers fed diets with different soybean oil availabilities in the rumen. Anim Feed Sci Technol 2013. [DOI: 10.1016/j.anifeedsci.2013.01.011] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
41
|
|
42
|
Xhixha G, Bezzon GP, Broggini C, Buso GP, Caciolli A, Callegari I, De Bianchi S, Fiorentini G, Guastaldi E, Kaçeli Xhixha M, Mantovani F, Massa G, Menegazzo R, Mou L, Pasquini A, Alvarez CR, Shyti M. The worldwide NORM production and a fully automated gamma-ray spectrometer for their characterization. J Radioanal Nucl Chem 2012. [DOI: 10.1007/s10967-012-1791-1] [Citation(s) in RCA: 56] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
43
|
Caciolli A, Baldoncini M, Bezzon GP, Broggini C, Buso GP, Callegari I, Colonna T, Fiorentini G, Guastaldi E, Mantovani F, Massa G, Menegazzo R, Mou L, Alvarez CR, Shyti M, Zanon A, Xhixha G. A new FSA approach for in situ γ ray spectroscopy. Sci Total Environ 2012; 414:639-645. [PMID: 22137648 DOI: 10.1016/j.scitotenv.2011.10.071] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/01/2011] [Revised: 10/27/2011] [Accepted: 10/31/2011] [Indexed: 05/31/2023]
Abstract
An increasing demand of environmental radioactivity monitoring comes both from the scientific community and from the society. This requires accurate, reliable and fast response preferably from portable radiation detectors. Thanks to recent improvements in the technology, γ spectroscopy with sodium iodide scintillators has been proved to be an excellent tool for in-situ measurements for the identification and quantitative determination of γ ray emitting radioisotopes, reducing time and costs. Both for geological and civil purposes not only (40)K, (238)U, and (232)Th have to be measured, but there is also a growing interest to determine the abundances of anthropic elements, like (137)Cs and (131)I, which are used to monitor the effect of nuclear accidents or other human activities. The Full Spectrum Analysis (FSA) approach has been chosen to analyze the γ spectra. The Non Negative Least Square (NNLS) and the energy calibration adjustment have been implemented in this method for the first time in order to correct the intrinsic problem related with the χ(2) minimization which could lead to artifacts and non physical results in the analysis. A new calibration procedure has been developed for the FSA method by using in situ γ spectra instead of calibration pad spectra. Finally, the new method has been validated by acquiring γ spectra with a 10.16 cm × 10.16 cm sodium iodide detector in 80 different sites in the Ombrone basin, in Tuscany. The results from the FSA method have been compared with the laboratory measurements by using HPGe detectors on soil samples collected particular, the (137)Cs isotopes has been implemented in the analysis since it has been found not negligible during the in-situ measurements.
Collapse
Affiliation(s)
- A Caciolli
- Istituto Nazionale di Fisica Nucleare, Padova Section, Via Marzolo 8-35131 Padova, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Rossi D, Pistilli B, Morale D, Baldelli, Casadei V, Benedetti G, Alessandroni P, Catalano V, Giordani P, Graziano F, Fedeli SL, Fiorentini G. "Short Course" of Nonpegylated Liposomal Doxorubicin Plus Paclitaxel and Trastuzumb as Primary Systemic Therapy for Operable and Locally-Advanced Breast Cancer: A Phase II Study (PacLiDox 07). World J Oncol 2011; 2:245-251. [PMID: 29147255 PMCID: PMC5649686 DOI: 10.4021/wjon393w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/06/2011] [Indexed: 11/29/2022] Open
Abstract
Background Schedules with anthracyclines and taxanes are one of the best options for primary chemotherapy. The addition of trastuzumab showed an impressive percentage of pathological complete responses in Buzdar trial (66.7%). Recently, nonpegylated liposome-encapsulated doxorubicin (NLD) has been widely used in advanced breast cancer with high response rates (98.1 % in Cortes study). The aims of our study were to assess pathological responses and toxicity of NLD plus paclitaxel (and trastuzumab in patients with HER2 overexpression). Methods Thirty patients entered the study: 9 locally advanced and 21 operable. Median age was 58.5 years (range: 31-73). 23 patients without HER2 overexpression (or FISH not amplified) were treated with NLD 50 mg/m2 every three weeks for 3 courses and weekly paclitaxel 80 mg/m2 for 8 courses. 7 patients with HER2 overexpression or FISH amplified were treated with the same schedules plus trastuzumab (Herceptin) 4 mg/kg for the first administration and 2 mg/kg for the following 7 weekly administrations. Results Pathological complete response (pCR) was documented in 1 patient (treated with trastuzumab); no residual tumor (infiltrating or “in situ”) on breast was documented in other 2 patients. Objective clinical responses were documented in 22 patients (73.3%): 8 complete, 10 partial and 4 “minimal” responses. 7 patients have shown stable and 1 progressive disease. Clinical response in patients with HER2 overexpression treated with trastuzumab was 100% (4 complete and 3 partial responses). Conservative surgery was performed in 8 (38%) and mastectomy in 13 (62%) out of 21 operable patients; however, 7 out of 14 responding patients with operable disease underwent quadrantectomy (50%). Main toxicity was neutropenia: febrile in 2 patients (7%) and gr. 3-4 in 13 (43%). Other grade 3 toxicities were as follows: vomiting in 1 patient, asthenia in 1 patient, joint symptom in 1 patient. 3 patients were withdrawn from the study. No episodes of left ventricular ejection fraction (LVEF) < 50% were recorded (with a median reduction of 8%). Conclusions A “short course” of paclitaxel and NLD is active in terms of clinical response and conservative surgery for patients with potentially operable and locally advanced breast cancer; toxicity was manageable. High activity of the combination with trastuzumab has been confirmed. However, with this “short course” schedule, the result in term of clinical responses didn't turn into complete pathological responses.
Collapse
Affiliation(s)
- D Rossi
- Oncology Unit, Marche Nord Hospital, S. Salvatore, Italy
| | - B Pistilli
- Oncolgy Unit, Macerata General Hospital, Italy
| | - D Morale
- Oncology Unit, Ascoli Piceno General Hospital, Italy
| | - Baldelli
- Oncology Unit, Marche Nord Hospital, S. Salvatore, Italy
| | - V Casadei
- Oncology Unit, Marche Nord Hospital, S. Salvatore, Italy
| | - G Benedetti
- Oncolgy Unit, Macerata General Hospital, Italy
| | - P Alessandroni
- Oncology Unit, Marche Nord Hospital, S. Salvatore, Italy
| | - V Catalano
- Oncology Unit, Marche Nord Hospital, S. Salvatore, Italy
| | - P Giordani
- Oncology Unit, Marche Nord Hospital, S. Salvatore, Italy
| | - F Graziano
- Oncology Unit, Marche Nord Hospital, S. Salvatore, Italy
| | - S Luzi Fedeli
- Oncology Unit, Marche Nord Hospital, S. Salvatore, Italy
| | - G Fiorentini
- Oncology Unit, Marche Nord Hospital, S. Salvatore, Italy
| |
Collapse
|
45
|
Pirrotta MT, Bernardeschi P, Fiorentini G. Targeted-therapy in advanced renal cell carcinoma. Curr Med Chem 2011; 18:1651-7. [PMID: 21428882 DOI: 10.2174/092986711795471293] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2010] [Accepted: 03/18/2011] [Indexed: 11/22/2022]
Abstract
Surgery has been the mainstay of renal cell carcinoma (RCC) treatment for resectable tumours. In stages I-III disease, nephrectomy is the standard of care and may be curative. Historically, patients presenting with stage IV disease may achieve improved survival with debulking nephrectomy, which is commonly performed prior to systemic therapy. The response rate of immunotherapy is low, with a smaller percentage exhibiting complete remission upon treatment. Therefore, new therapeutic approaches against metastatic RCC are necessary. Recently, molecular mechanisms responsible for the proliferation of RCC have been identified, and molecular targeted therapy has developed. Clear cell RCC commonly features mutation or inactivation of the von Hippel- Lindau (VHL) gene and resultant over-expression of vascular endothelial growth factor (VEGF). The first drug to validate VEGF as a target in the treatment of clear cell RCC was the monoclonal antibody bevacizumab. Sunitinib is now a standard first-line therapy for advanced disease and sorafenib is among the second-line treatment options. Mammalian target of rapamycin (mTOR) is a second validated therapeutic target as the mTOR inhibitor temsirolimus has been shown to prolong survival in first-line treatment of poor prognosis RCC of all histologies. Everolimus is an oral mTOR inhibitor and has been shown to prolong progression-free survival (PFS) when used in second-line treatment. This review describes recent advances in molecular targeted therapy for metastatic RCC, focusing on chemical structure and mechanism of action of VEGFR and mTOR inhibitors.
Collapse
Affiliation(s)
- M T Pirrotta
- Oncology Unit, San Giuseppe Hospital, Via Boccaccio 20, 50053 Empoli, Italy.
| | | | | |
Collapse
|
46
|
Montagnani F, Chiriatti A, Turrisi G, Francini G, Fiorentini G. A systematic review of FOLFOXIRI chemotherapy for the first-line treatment of metastatic colorectal cancer: improved efficacy at the cost of increased toxicity. Colorectal Dis 2011; 13:846-52. [PMID: 20070327 DOI: 10.1111/j.1463-1318.2010.02206.x] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
AIM The simultaneous administration of irinotecan, 5-fluorouracil, folinic acid and oxaliplatin (FOLFOXIRI) has been compared with standard 5-fluorouracil, folinic acid and irinotecan (FOLFIRI) in randomized trials in metastatic colorectal cancer patients. A superior efficacy of FOLFOXIRI has been reported by some authors, but others have failed to show any differences and do not recommend its use because of greater cost and toxicity. We performed a systematic review of the literature to analyse efficacy and toxicity of FOLFOXIRI. METHOD Odds ratios (OR) with 95% confidence intervals (CI) were used to analyse dichotomous variables. Hazard ratios (HR) for progression and death were combined with an inverse variance method based on logarithmic conversion. A fixed-effect model and Mantel-Haenszel's method were used. Heterogeneity was tested with Cochrane's Q test and I(2) test. RESULTS A significant increase in response rate (OR 2.04; P < 0.01) was associated with treatment by FOLFOXIRI and a benefit was also shown by the HR for progression (HR 0.72; P < 0.01) and death (HR 0.71; P < 0.01). Analysis for toxicity found a significant increase associated with FOLFOXIRI except for anaemia, fatigue and febrile neutropenia. CONCLUSION FOLFOXIRI confers significant benefit in progression-free survival, survival, response and R0 resection rates but is more toxic compared with FOLFIRI.
Collapse
Affiliation(s)
- F Montagnani
- Oncology Unit, S. Giuseppe Hospital, Florence, Italy.
| | | | | | | | | |
Collapse
|
47
|
|
48
|
Rossi G, Mavrogenis AF, Rimondi E, Ciccarese F, Tranfaglia C, Angelelli B, Fiorentini G, Bartalena T, Errani C, Ruggieri P, Mercuri M. Selective arterial embolisation for bone tumours: experience of 454 cases. Radiol Med 2011; 116:793-808. [PMID: 21424560 DOI: 10.1007/s11547-011-0670-0] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2010] [Accepted: 11/03/2010] [Indexed: 01/14/2023]
Abstract
PURPOSE The authors present the experience of a single institution with selective arterial embolisation for primary and metastatic bone tumours. MATERIALS AND METHODS A total of 365 patients were treated with 454 embolisation procedures from December 2002 to April 2010. Embolisation was the primary treatment for benign bone tumours, adjuvant treatment to surgery for benign and malignant bone tumours and palliative treatment for bone sarcomas and metastases. Indications for repeat embolisation included pain or imaging evidence of progressive disease: 105 patients had repeat embolisation at the same location at an interval of 1-3 months; 260 patients had one embolisation, 78 had two and 29 had three or more. In all patients, N-2-butyl cyanoacrylate (NBCA) in 33% lipiodol was the embolic agent used. RESULTS A total of 419 of the 454 embolisations (93%) were technically successful. In 35 cases, embolisation was not feasible because of poor lesion vascularisation (21 patients with bone metastases and two with aneurysmal bone cysts), origin of the Adamkiewicz artery in the embolisation field (four patients with bone metastases and one with aneurysmal bone cyst), atheromatosis and arteriosclerosis (five patients with bone metastases) and anatomical and technical problems such as small-calibre vessels, many branches and acute vessel angles (two patients with bone metastases). A clinical response was achieved in 406 of the 419 procedures (97%), and no response in 13 procedures in patients with pelvis and sacrum tumours. Complications included postembolisation syndrome in 81 patients (22%), transient paraesthesias in 41 (11%), skin breakdown and subcutaneous necrosis at the shoulder and pelvis in five (1.4%) and paresis of the sciatic nerve in one (0.3%). CONCLUSIONS We recommend embolisation as primary or palliative treatment or an adjunct to surgery for tumours of variable histology. Strict adherence to the principles of transcatheter embolisation is important. Arteries feeding the tumour and collaterals must be evaluated carefully and catheterised superselectively to protect the normal tissues. NBCA is considered the most appropriate embolic agent for small-vessel occlusion without major complications.
Collapse
Affiliation(s)
- G Rossi
- Department of Interventional Angiographic Radiology, Istituto Ortopedico Rizzoli, Via Di Barbiano 1/10, 40136, Bologna, Italy
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Aliberti C, Benea G, Tilli M, Fiorentini G. Transarterial chemoembolization (TACE) of liver metastases (LM) from colorectal carcinoma (CRC) adopting drug eluting beads preloaded with irinotecan (DEBIRI): Results of a phase II study on 82 patients. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.4092] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4092 Background: DC beads are new embolic microspheres capable to load IRI. The present phase II study investigated response and side effects after TACE adopting DEBIRI in 82 patients with LM from CRC not resectable and in progression after two lines of chemtherapy. Methods: A total of 185 TACE procedures were performed. A suspension of polyvinyl-alcohol beads (DC Bead) preloaded with Irinotecan ( 81 TACE procedures with 2ml of microspheres preloaded with 100mgr of Irinotecan and 104 with 4ml loaded with 200mgr of Irinotecan) was delivered selectively into hepatic arteries. All pts received a well defined prophylactic treatment against nausea and vomiting, infections, and upper quadrant right pain (UQRP).Tropisetron, hydration, antibiotics, morphine and intra-arterial lidocaine was delivered as reported in previous experiences ( ASCO GI abs 356,2007; IN VIVO. 21, 6, 2007). Follow-up studies were performed by contrast enhanced spiral multislice computed tomography (MsCT) 1 month after the procedures and every 3 months or when clinically required. Quality of life (QoL) was assessed by Edmonton SAS improvement scale before, after TACE and then monthly. Results: We obtained 100% technical success in TACEs performed, and no complications due to the procedure occurred. Patients developed a postembolization-syndrome with the following side effects : UQRP (G2), fever (G2), nausea (G2) and increased transaminases (G2–3) in 40%,80%,80%,70% respectively out of 185 procedures done. One pt presented acute pancreatitis. The median follow-up was 18.2 months. Within 1 month after treatment, CT scan showed significant ( 75–100%) reduction of metastatic contrast enhancement in all lesions treated. Therapeutic response (according to RECIST was observed in 78% of patients. After TACE. 75 out 82 pts (90%) declare a general improvement of QoL long lasting. Conclusions: We suggest that TACE with DEBIRI could be a palliative therapy for LM from CRC. Our promising experience need to be confirmed with further phase III studies. Mid and long-term results need to be carefully evaluated comparing them with systemic chemotherapy. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- C. Aliberti
- Delta Hospital, Lagosanto, Ferrara, Italy; Dipartimento di Oncologia Medica AUSL Empoli, Empoli, Italy
| | - G. Benea
- Delta Hospital, Lagosanto, Ferrara, Italy; Dipartimento di Oncologia Medica AUSL Empoli, Empoli, Italy
| | - M. Tilli
- Delta Hospital, Lagosanto, Ferrara, Italy; Dipartimento di Oncologia Medica AUSL Empoli, Empoli, Italy
| | - G. Fiorentini
- Delta Hospital, Lagosanto, Ferrara, Italy; Dipartimento di Oncologia Medica AUSL Empoli, Empoli, Italy
| |
Collapse
|
50
|
Fiorentini G, Aliberti C, Benea G, Tilli M, Del Conte A. A pilot study of trans arterial chemo-embolization (TACE) with drug eluting beads irinotecan (IRI) preloaded (DEBI) for liver metastases (LM) from uveal melanoma (UM): An Italian National Study. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.20010] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|